BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Basu A, Lambring CB. Akt Isoforms: A Family Affair in Breast Cancer. Cancers (Basel) 2021;13:3445. [PMID: 34298660 DOI: 10.3390/cancers13143445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wainstein E, Maik-Rachline G, Blenis J, Seger R. AKTs do not translocate to the nucleus upon stimulation but AKT3 can constitutively signal from the nuclear envelope. Cell Rep 2022;41:111733. [PMID: 36476861 DOI: 10.1016/j.celrep.2022.111733] [Reference Citation Analysis]
2 Pang K, Wang W, Qin J, Shi Z, Hao L, Ma Y, Xu H, Wu Z, Pan D, Chen Z, Han C. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm 2022;3. [DOI: 10.1002/mco2.175] [Reference Citation Analysis]
3 Lv Y, Mou Y, Su J, Liu S, Ding X, Yuan Y, Li G, Li G. The Inhibitory Effect of Resina draconis on the Proliferation of MCF-7 Breast Cancer Cells, and its Mechanism: An Investigation Using Network Pharmacology-Based Analysis.. [DOI: 10.21203/rs.3.rs-2253225/v1] [Reference Citation Analysis]
4 Grassilli S, Bertagnolo V, Brugnoli F. Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches. Diagnostics 2022;12:2139. [DOI: 10.3390/diagnostics12092139] [Reference Citation Analysis]
5 Zhou H, Wang L, Liu S, Wang W. The role of phosphoinositide 3-kinases in immune-inflammatory responses: potential therapeutic targets for abdominal aortic aneurysm. Cell Cycle 2022;:1-26. [PMID: 35792922 DOI: 10.1080/15384101.2022.2094577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sun EC, Dong SS, Li ZJ, Li CX. Clinicopathological Significance of AKT1 and PLK1 Expression in Oral Squamous Cell Carcinoma. Dis Markers 2022;2022:7300593. [PMID: 35756492 DOI: 10.1155/2022/7300593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hua L, Zhang Q, Zhu X, Wang R, You Q, Wang L. Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors. J Med Chem 2022;65:8091-112. [PMID: 35686733 DOI: 10.1021/acs.jmedchem.2c00316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Grassilli S, Brugnoli F, Cairo S, Bianchi N, Judde J, Bertagnolo V. Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype. JPM 2022;12:993. [DOI: 10.3390/jpm12060993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Khezri MR, Jafari R, Yousefi K, Zolbanin NM. The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Experimental and Molecular Pathology 2022. [DOI: 10.1016/j.yexmp.2022.104787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zhang ZD, Wen B, Li DJ, Deng DX, Wu XD, Cheng YW, Liao LD, Long L, Dong G, Xu LY, Li EM. AKT serine/threonine kinase 2-mediated phosphorylation of fascin threonine 403 regulates esophageal cancer progression. Int J Biochem Cell Biol 2022;145:106188. [PMID: 35219877 DOI: 10.1016/j.biocel.2022.106188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sousa C, Silva-lima B, Videira M. Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers. Onco 2022;2:36-55. [DOI: 10.3390/onco2010004] [Reference Citation Analysis]
12 Azzalini E, Tierno D, Bartoletti M, Barbazza R, Giorda G, Puglisi F, Cecere SC, Losito NS, Russo D, Stanta G, Canzonieri V, Bonin S. AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization. Cancers (Basel) 2022;14:304. [PMID: 35053468 DOI: 10.3390/cancers14020304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kim JY, Park CS, Jang S, Seol H, Seong M, Noh WC, Park I, Kim H. The Significance of p-AKT1 as a Prognostic Marker and Therapeutic Target in Patients With Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Positive Early Breast Cancer. J Breast Cancer 2022;25:387. [DOI: 10.4048/jbc.2022.25.e43] [Reference Citation Analysis]
14 Salahudeen AA, Yuki K, Seoane JA, Mah AT, Smith AR, Kolahi K, De la O SM, Hart DJ, Ding J, Ma Z, Barkal S, Shukla ND, Zhang C, Cantrell MA, Batish A, Usui T, Root D, Hahn W, Curtis C, Kuo CJ. Pan-cancer organoid validation of tumor outlier chromosomal amplification events.. [DOI: 10.1101/2021.10.05.463147] [Reference Citation Analysis]